Clinical Presentations, Microbiology, Antibiotic Resistance Patterns and Management Outcomes of Culture-proven Infection Among Adolescent and Adult in A Tertiary Hospital in Saudi Arabia
Withdrawn
- Conditions
- Culture-proven Infection
- Interventions
- Other: Culture
- Registration Number
- NCT04395586
- Lead Sponsor
- Aseer Central Hospital
- Brief Summary
The characteristics of patients as well as microbiologic profile of culture-proven infection will be studies in conjunction with clinical outcome within 28-days
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Any individual aged ≥13 year old requested for him/her bacterial/fungal culture.
- Able to provide a written informed consent.
Exclusion Criteria
- Age <13 years old.
- Unable/unwilling to provide a written informed consent.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Culture-proven infected patients Culture -
- Primary Outcome Measures
Name Time Method Mortality 28 days All-cause and disease specific mortality
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What Gram-negative pathogens and antibiotic resistance mechanisms are prevalent in culture-proven infections among adolescents and adults in Saudi Arabia?
How does culture-guided antibiotic therapy improve clinical outcomes compared to empirical treatment protocols in multidrug-resistant infections?
Which biomarkers correlate with response to targeted antimicrobial therapies in culture-proven infections with ESBL-producing organisms?
What adverse events are associated with extended-spectrum beta-lactamase (ESBL) infections and how are they managed in Saudi tertiary hospitals?
Are combination antimicrobial regimens more effective than monotherapies against carbapenem-resistant Klebsiella pneumoniae in adult culture-proven infections?